Ophthotech Corp (OPHT) : Jhl Capital Group reduced its stake in Ophthotech Corp by 8.12% during the most recent quarter end. The investment management company now holds a total of 3,000,000 shares of Ophthotech Corp which is valued at $107,610,000 after selling 265,000 shares in Ophthotech Corp , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Ophthotech Corp makes up approximately 19.99% of Jhl Capital Group’s portfolio.
Other Hedge Funds, Including , Peak6 Investments sold out all of its stake in OPHT during the most recent quarter. The investment firm sold 5,716 shares of OPHT which is valued $205,033.Finemark National Bank Trust boosted its stake in OPHT in the latest quarter, The investment management firm added 90 additional shares and now holds a total of 236 shares of Ophthotech Corp which is valued at $8,376. Teacher Retirement System Of Texas sold out all of its stake in OPHT during the most recent quarter. The investment firm sold 3,582 shares of OPHT which is valued $112,367. Quantitative Investment Management sold out all of its stake in OPHT during the most recent quarter. The investment firm sold 6,700 shares of OPHT which is valued $230,614.
Ophthotech Corp opened for trading at $35.29 and hit $36.26 on the upside on Monday, eventually ending the session at $35.33, with a gain of 0.23% or 0.08 points. The heightened volatility saw the trading volume jump to 6,31,630 shares. Company has a market cap of $1,261 M.
Ophthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate Zimura an inhibitor of complement factor C5 is developed for the treatment of geographic atrophy (a form of dry AMD) and in combination with anti-VEGF therapy and Fovista for the treatment of wet AMD. Both Fovista and Zimura are aptamers single strands of nucleic acid that binds with affinity to targets.